Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: A retrospective, multi-center descriptive study: Comment on the article by Nakano K et al

Affiliations

Editorial

Yukitomo Urata. Mod Rheumatol. 2023.

. 2023 Apr 13;33(3):631.

doi: 10.1093/mr/roac134.

¹ Department of Rheumatology, Tsugaru General Hospital, United Municipalities of Tsugaru, Aomori, Japan.

No abstract available

Comment on

Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study.
Nakano K, Tanaka Y, Saito K, Kaneko Y, Saito S, Tanaka M, Saito R, Fujii T, Kuramoto N, Sugimoto N, Takada H, Harigai M, Sasaki S, Suzuki Y. Nakano K, et al. Mod Rheumatol. 2022 Jan 5;32(1):41-49. doi: 10.1080/14397595.2020.1847775. Mod Rheumatol. 2022. PMID: 33164614
Response to Dr Urata's Letter to the Editor of Modern Rheumatology regarding a study of "Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders".
Nakano K. Nakano K. Mod Rheumatol. 2023 Apr 13;33(3):632. doi: 10.1093/mr/roac135. Mod Rheumatol. 2023. PMID: 36330538 No abstract available.